- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00642616
Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease
April 12, 2017 updated by: Mannkind Corporation
A Phase 3, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere® Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12 Months Treatment Period With a 2 Month Follow-up
Examine the effects of TI in combination with an anti-diabetic regimen including inhaled insulin versus anti-diabetic treatment without inhaled insulin on lung function & pulmonary safety
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
RU
-
Kemerovo, RU, Russian Federation, 650066
-
Moscow, RU, Russian Federation, 105120
-
St Petersburg, RU, Russian Federation, 198013
-
St. Petersburg, RU, Russian Federation, 191015
-
St. Petersburg, RU, Russian Federation, 191119
-
St. Petersburg, RU, Russian Federation, 194354
-
-
RUS
-
Yaroslavl, RUS, Russian Federation, 150002
-
-
-
-
UA
-
Kiev, UA, Ukraine, 04114
-
Kyiv, UA, Ukraine, 01021
-
-
-
-
California
-
Mission Hills, California, United States, 91345
-
San Diego, California, United States, 92117
-
-
Florida
-
Palm Harbor, Florida, United States, 34684
-
-
Michigan
-
Flint, Michigan, United States, 48504
-
-
North Carolina
-
Morehead City, North Carolina, United States, 28557
-
-
Oregon
-
Medford, Oregon, United States, 97504
-
-
South Carolina
-
Greenville, South Carolina, United States, 29615
-
Spartanburg, South Carolina, United States, 29302
-
-
Texas
-
Dallas, Texas, United States, 75231
-
Dallas, Texas, United States, 75225
-
-
Washington
-
Federal Way, Washington, United States, 98003
-
Tacoma, Washington, United States, 98405
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Asthma
- Physician diagnosis of asthma with history of any or all of the following: recurrent wheezing, recurrent chest tightness, recurrent difficulty breathing, or cough, particularly worse at nighttime
- Never smoked or former smokers (= 6 months since cessation)
- ≥18 years of age
- Prebronchodilator Forced Expiratory Volume in 1sec (FEV1) ≥ 60% Third National Health and Nutrition Examination Survey (NHANES III) predicted, prebronchodilator total lung capacity (TLC) ≥ 80% predicted Intermountain Thoracic Society (ITS), and prebronchodilator single breath carbon monoxide diffusing capacity of the lung (DLco) (unc) ≥70% predicted (Miller)
- < 30% day-to-day variability in daily morning Peak expiratory Volume (PEF) during the 2-week run-in period
- Significant improvement in pre- to postbronchodilator spirometry (defined as an increase from baseline of ≥ 12% and ≥ 200 mL in FEV1 or Forced Vital Capacity [FVC]) at Screening/Visit 1 or documented significant improvement in pre- to postbronchodilator spirometry (as defined above) within past 12 months in subject's medical records or a documented positive methacholine challenge test within the past 12 months
COPD
- Physician diagnosis of COPD (including emphysema and/or chronic bronchitis), history of dyspnea and/or intermittent or daily chronic cough with or without sputum production, not attributable to any other known cause
- Former smoker (≥ 6 months since cessation) with smoking history of ≥ 10 pack years
- ≥40 years of age
- Postbronchodilator FEV1/FVC ratio < 70%
- Postbronchodilator FEV1 ≥ 50% NHANES III predicted, total lung capacity (TLC) ≥ 80% predicted ITS, and DLco (unc) ≥ 50% predicted (Miller)
Both
- Clinical diagnosis of Type1 or 2 diabetes mellitus for ≥ 12 months and no change in anti-diabetic regiment for at least 90-days prior to screening
- BMI of, < 39 kg/m2
- Urine cotinine level ≤ 100ng/dL
- Clinical diagnosis of obstructive lung disease
- HbA1C > 6.5% ≤ 11.5%
Exclusion Criteria:
- History of pulmonary exacerbation within 8 weeks of screening/V1 or between V1 and V2
- Use of systemic corticosteroids or antibiotics for respiratory illness within 8 weeks of screening/V1 OR between V1 and V2
- Increase from baseline in the use of short-acting bronchodilator or short-acting anticholinergic agents, or the combination of the 2, by ≥6 puffs or ≥3 nebulizer treatments per day for ≥ 2 days
- Treatment with supplemental oxygen therapy, room air oxygen saturation, 94% or history of intubation or ICU admission for respiratory illness in the past 5 yrs.
- Greater than 2 hospitalizations or ER or urgent care visits or required >3 courses of systemic steroid in the past 12 months for respiratory illness
- Use of Symlin® (pramlintide acetate) within the preceding 90 days
- Two or more severe hypoglycemic episodes within 6 months of screening or episode of severe hypoglycemia between Screening and Baseline
- Previous exposure to any inhaled insulin product
- Currently using an insulin delivery pump
- Requires significant change (define as initiation of a new medication or change in the dose or frequency of the controller medications) in the asthma or COPD therapeutic regimen within 8 weeks of Screening/Visit 1 (Week -4) or between Visit 1 and Baseline/Visit 2
- Severe complications of diabetes mellitus, in the opinion of the PI or sub-investigator, including symptomatic autonomic neuropathy; disabling peripheral neuropathy; active proliferative retinopathy; nephropathy with renal failure, renal transplant and/or dialysis; history of foot ulcers; nontraumatic amputations due to gangrene; and/or vascular claudication
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Technosphere® Insulin (Asthma)
Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Asthma
|
Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents
Other Names:
|
Active Comparator: Usual Care (Asthma)
Usual anti diabetic care in Diabetic participants with Asthma
|
Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin
|
Experimental: Technosphere® Insulin (COPD)
Technosphere® Insulin Inhalation Powder administered prandially in diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
|
Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents
Other Names:
|
Active Comparator: Usual Care (COPD)
Usual anti diabetic care in Diabetic participants with Chronic Obstructive Pulmonary disease (COPD)
|
Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Post-bronchodilator FEV1 From Baseline to Week 52
Time Frame: 52 Weeks
|
Post-bronchodilator Forced Expiratory Volume in 1 second (FEV1) is measured at the pulmonary function laboratory.
|
52 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Asthma Exacerbation by Treatment Arm
Time Frame: Baseline to Week 52
|
Number of participants who experienced worsening of asthma symptoms
|
Baseline to Week 52
|
Number of Participants With COPD Exacerbation by Treatment Arm
Time Frame: Baseline to Week 52
|
Number of participants who experienced worsening of COPD symptoms
|
Baseline to Week 52
|
Change in HbA1C From Baseline to Week 52
Time Frame: Baseline, week 52
|
Baseline, week 52
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Chief Medical Officer, Mannkind Corporation
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2009
Primary Completion (Actual)
November 1, 2014
Study Completion (Actual)
November 1, 2014
Study Registration Dates
First Submitted
March 21, 2008
First Submitted That Met QC Criteria
March 24, 2008
First Posted (Estimate)
March 25, 2008
Study Record Updates
Last Update Posted (Actual)
April 14, 2017
Last Update Submitted That Met QC Criteria
April 12, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Respiratory Tract Diseases
- Immune System Diseases
- Autoimmune Diseases
- Hypersensitivity, Immediate
- Endocrine System Diseases
- Bronchial Diseases
- Respiratory Hypersensitivity
- Hypersensitivity
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Diabetes Mellitus, Type 1
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Asthma
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Insulin
Other Study ID Numbers
- MKC-TI-134
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Technosphere® Insulin
-
Mannkind CorporationCompletedHealthy VolunteersUnited States
-
Mannkind CorporationCompletedType 2 DiabetesUnited States, Russian Federation, Brazil, Ukraine
-
Mannkind CorporationCompleted
-
Mannkind CorporationCompletedType 1 Diabetes MellitusUnited States, Brazil, Russian Federation, Ukraine
-
Mannkind CorporationCompletedChronic Obstructive Pulmonary Disease (COPD)Netherlands, United States, Austria, United Kingdom
-
Mannkind CorporationCompleted
-
South Orange County EndocrinologyMannkind CorporationWithdrawn
-
Mannkind CorporationCompletedType 2 Diabetes Mellitus
-
Mannkind CorporationCompleted
-
Mannkind CorporationCompleted